Adis Drug Profile

Drugs & Aging

, Volume 27, Issue 1, pp 77-85

First online:

Hylan G-F 20 Single-Injection Formulation

  • James E. FramptonAffiliated withAdis, a Wolters Kluwer Business Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Hylan G-F 20, a cross-linked hyaluronic acid derivative, is an elastoviscous, high-molecular-weight (average 6000 kDa) fluid with rheological properties similar to those of knee synovial fluid of healthy young individuals.

In a 26-week, randomized, double-blind, multi-centre study in patients with symptomatic primary osteoarthritis of the knee (n = 253), one intraarticular injection of hylan G-F 20 (single-injection formulation) into the target knee significantly relieved pain (as measured by the Western Ontario and McMaster Universities Osteoarthritis Index pain [WOMAC A] subscale), including pain while walking on a flat surface (as assessed by the WOMAC A1 subscore), compared with placebo.

Observer-reported disease status and patient-reported health status were also significantly improved in hylan G-F 20-treated patients compared with placebo-treated patients.

A single intra-articular injection of hylan G-F 20 was generally well tolerated, with an adverse event profile similar to that of placebo.

Repeat administration of hylan G-F 20 after 6 months had a similar tolerability profile to that of the initial injection. However, no patient who developed a target-knee adverse event after their first injection experienced such an event following their second injection.